# 🔄 ARNI Transition Protocols

## 🚨 Critical Safety Warning

**Angioedema Risk:** Separate an ACE inhibitor and sacubitril/valsartan by at least 36 hours in either direction. Renal impairment affects starting dose and monitoring; pharmacokinetic accumulation does not validate a calculated 3-30-day washout protocol.

## 💊 Understanding ARNI: Sacubitril/Valsartan

### 🎯 Mechanism of Action and Clinical Benefits

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) therapy represents a paradigm shift in heart failure management, combining angiotensin II receptor blockade with neprilysin inhibition to provide superior cardiovascular outcomes compared to ACE inhibitor monotherapy.

#### Dual Mechanism Benefits:

##### 🛡️ Angiotensin II Receptor Blockade

- **Vascular effects:** Vasodilation and reduced afterload
- **Cardiac remodeling:** Prevention of maladaptive changes
- **Aldosterone suppression:** Reduced sodium retention
- **Blood pressure reduction:** Consistent antihypertensive effect

##### ⚡ Neprilysin Inhibition

- **Natriuretic peptide enhancement:** Increased BNP and ANP activity
- **Improved hemodynamics:** Enhanced venous and arterial dilation
- **Diuretic synergy:** Augmented natriuresis and diuresis
- **Anti-fibrotic effects:** Reduced myocardial fibrosis

#### PARADIGM-HF Trial Results:

The landmark PARADIGM-HF trial demonstrated superior outcomes with sacubitril/valsartan compared to enalapril in heart failure patients with reduced ejection fraction.

##### Key Clinical Outcomes (vs. Enalapril):

**Cardiovascular Death**\
20% relative reduction\
3.4% absolute reduction **Heart Failure Hospitalization**\
21% relative reduction (HR 0.79)\
approximately 2.8% absolute reduction\
(rate 12.8% vs 15.6%) **All-Cause Mortality**\
16% relative reduction\
2.8% absolute reduction

## ⚠️ Angioedema Risk and Washout Requirements

### 🧬 Pathophysiology of Dual Inhibition Risk

The combination of ACE inhibition and neprilysin inhibition creates a synergistic risk for angioedema through complementary pathways affecting bradykinin metabolism and clearance.

#### Mechanism of Enhanced Angioedema Risk:

- **ACE inhibition:** Reduces bradykinin degradation by blocking angiotensin-converting enzyme
- **Neprilysin inhibition:** Further reduces bradykinin clearance through blocked neutral endopeptidase
- **Synergistic effect:** Dual pathway blockade dramatically increases bradykinin levels
- **Clinical consequence:** Substantially elevated angioedema risk compared to monotherapy

##### Clinical Evidence of Risk:

Concurrent ACE inhibition and neprilysin inhibition increase angioedema risk. ARNI must not overlap an ACE inhibitor; use at least 36 hours of separation in either direction as specified by labeling.

## Kidney impairment: separate exposure from the labeled safeguard

Renal impairment can increase exposure to renally cleared ACE inhibitors and influences ARNI starting-dose selection and follow-up. It does not establish a validated drug-by-eGFR table of 3-30-day washout intervals. Follow the minimum 36-hour separation, assess the individual clinically, and use the product-specific starting dose.

## 📋 Evidence-Based Washout Protocols

### 🎯 Risk-Stratified Washout Guidelines

Safe transition requires the labeled minimum interval, a separately selected starting dose, medication reconciliation, and clinical follow-up. No pharmacokinetic multiplier in this lesson defines a validated longer washout.

1 **Pre-Transition Assessment:** Evaluate current ACE inhibitor, renal function (eGFR), and baseline angioedema risk factors 2 **Risk Stratification:** Classify patients into low, moderate, or high-risk categories based on elimination pathway and renal function 3 **Individualized Washout:** Record the exact last ACE inhibitor dose and enforce the labeled minimum 36-hour separation; do not derive a longer interval from an unvalidated calculator 4 **Medication reconciliation:** Stop the ACE inhibitor and prevent duplicate ARB therapy; any interim treatment is an individualized prescribing decision, not routine bridge therapy 5 **ARNI Initiation:** Begin sacubitril/valsartan with appropriate monitoring and patient education about angioedema symptoms

#### Separate timing from dose selection

The labeled timing safeguard remains at least 36 hours. A longer apparent elimination half-life is not a validated clinical angioedema calculator. Severe kidney impairment, low prior RAAS exposure, BP, and volume status affect the starting dose and monitoring independently.

## Medication continuity during transition

Write the last ACE inhibitor dose, the first permitted ARNI dose, and which prescriptions to remove. ARNI already contains valsartan: do not continue a separate ARB. Do not routinely add an ARB simply to bridge a fabricated prolonged washout.

**Worked timing example:** Last ACE inhibitor Monday 8 am means no ARNI before Tuesday 8 pm. The treating clinician selects the starting dose separately; severe renal impairment generally calls for half the usual starting dose. Arrange early BP, creatinine, potassium, and symptom review. [Official prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f).

## 👥 Patient Selection and Safety Considerations

### 📋 Comprehensive Assessment Framework

Appropriate patient selection for ARNI therapy requires careful evaluation of benefits, risks, and individual patient characteristics, particularly in the chronic kidney disease population.

#### Ideal Candidates for ARNI Transition:

- **Heart failure with reduced ejection fraction:** EF ≤40% on guideline-directed medical therapy
- **Symptomatic patients:** NYHA Class II-IV despite optimal ACE inhibitor therapy
- **Stable renal function:** No recent acute kidney injury or dialysis dependence
- **Adequate blood pressure:** Systolic BP ≥100 mmHg consistently
- **Hyperkalemia tolerance:** Ability to maintain K+ \<5.2 mmol/L

#### Absolute Contraindications:

- **History of angioedema:** Any cause, particularly ACE inhibitor or ARB-related
- **Concurrent ACE inhibitor use:** Must complete appropriate washout period
- **Pregnancy:** Teratogenic risk with ARB component
- **Bilateral renal artery stenosis:** Risk of acute kidney injury
- **Severe hypotension:** Systolic BP \<90 mmHg consistently

#### Relative Contraindications and Cautions:

- **Advanced CKD (eGFR \<15 mL/min):** Limited experience, require specialist consultation
- **Hyperkalemia history:** Chronic K+ \>5.0 mmol/L, require enhanced monitoring
- **Age \>85 years:** Increased hypotension risk, start with lower doses
- **Recent hospitalization:** Wait for clinical stability before transition
- **Multiple antihypertensive agents:** Complex interaction management

## 📊 Post-Transition Monitoring and Safety

### 🔍 Comprehensive Surveillance Strategy

Successful ARNI implementation requires systematic monitoring protocols to ensure safety and optimize therapeutic benefits, particularly during the initial transition period.

#### Monitoring Timeline:

| Timepoint | Clinical Assessment | Laboratory Monitoring | Safety Focus | Dose Optimization |
|----|----|----|----|----|
| **1-3 days** | Symptoms, BP, HR | Not routinely required | Angioedema surveillance | Assess tolerance |
| **1-2 weeks** | Functional status, BP | Creatinine, K+, BUN | Hypotension, renal function | Consider dose increase |
| **4-6 weeks** | NYHA class, exercise tolerance | Complete metabolic panel | Electrolyte stability | Target dose achievement |
| **3 months** | QOL assessment, hospitalizations | BNP/NT-proBNP trend | Long-term safety | Maximal tolerated dose |

#### Patient Education Components:

- **Angioedema recognition:** Facial swelling, difficulty breathing, throat tightness
- **Emergency protocols:** When to seek immediate medical attention
- **Hypotension awareness:** Dizziness, lightheadedness, fall risk
- **Medication adherence:** Twice-daily dosing importance
- **Interaction awareness:** NSAIDs, potassium supplements, salt substitutes

## 🧮 ARNI Transition Safety Checklist

### 📊 Review the Transition Safeguards

Review the minimum interval and safety checks; these inputs do not calculate an individualized treatment order:

Current ACE Inhibitor: **eGFR (mL/min/1.73m²):** 60 mL/min/1.73m² **Patient Age (years):** 65 years History of angioedema (any cause) Recent heart failure hospitalization History of symptomatic hypotension High-dose ACE inhibitor therapy

#### ARNI Transition Safety Checks

## 📚 Sources

1.  **McMurray JJV, Packer M, Desai AS, et al; PARADIGM-HF Investigators.** Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. *N Engl J Med.* 2014;371(11):993-1004. [PMID: 25176015](https://pubmed.ncbi.nlm.nih.gov/25176015/). \[Source for: PARADIGM-HF primary composite HR 0.80 (20% RRR), CV death HR 0.80, HHF HR 0.79 (21%), all-cause mortality HR 0.84 (16%); N=8,442; sacubitril-valsartan vs enalapril.\]
2.  **Makani H, Messerli FH, Romero J, et al.** Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. *Am J Cardiol.* 2012;110(3):383-391. [PMID: 22521308](https://pubmed.ncbi.nlm.nih.gov/22521308/). \[Source for: ACE-I angioedema 0.30%, ARB 0.11%, baseline rates that inform the dual-inhibition risk discussion.\]
3.  **Solomon SD, McMurray JJV, Vaduganathan M, et al; FINEARTS-HF Committees and Investigators.** Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N Engl J Med.* 2024;391(16):1475-1485. [PMID: 39225278](https://pubmed.ncbi.nlm.nih.gov/39225278/). \[Source for: HFmrEF/HFpEF MRA evidence relevant to ARNI selection in non-HFrEF populations; primary RR 0.84 = 16% RRR.\]
4.  **Hoyer J, Schulte KL, Lenz T.** Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. *Clin Pharmacokinet.* 1993;24(3):230-254. [PMID: 8462229](https://pubmed.ncbi.nlm.nih.gov/8462229/). \[Source for: lisinopril, enalapril, ramipril half-life prolongation in CKD describing drug accumulation; this does not establish longer ARNI washout intervals.\]
5.  **Heidenreich PA, Bozkurt B, Aguilar D, et al.** 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Am Coll Cardiol.* 2022;79(17):e263-e421. [PMID: 35379503](https://pubmed.ncbi.nlm.nih.gov/35379503/). \[Source for: 2022 HF guideline ARNI Class 1 recommendation in HFrEF; 36-hour minimum washout from ACE-I; preferred over ACE-I or ARB monotherapy.\]
6.  **Vukadinović D, Vukadinović AN, Lavall D, et al.** Rate of Cough During Trials of ACE Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis. *Clin Pharmacol Ther.* 2019;105(3):652-660. [PMID: 29330882](https://pubmed.ncbi.nlm.nih.gov/29330882/). \[Source for: ACE-I cough rates in head-to-head ACE-vs-ARB context; cough is the most common reason for transition.\]

Sacubitril/valsartan must not overlap an ACE inhibitor. Follow the labeled minimum 36-hour separation and individualized specialist assessment.

## 🎯 Key Learning Points

**⚠️ Pharmacokinetic Impact:** Renal impairment can alter ACE inhibitor exposure, but it does not validate a 7-10-day ARNI washout rule. Follow the labeled minimum interval and individualized assessment. **🚨 Clinical Caution:** Kidney function, potassium, BP, angioedema history, and prior RAAS dose guide eligibility, starting dose, and monitoring. Do not substitute an unvalidated renal multiplier for the labeled timing safeguard. **🔄 Risk Stratification:** At least 36 hours separates ACE inhibitor and ARNI in either direction; the exact dose timing must be documented and understood. **🌉 Bridging Strategy:** Routine ARB bridging is not required; ARNI contains an ARB and must not overlap a separate ARB prescription. **💊 PARADIGM-HF Benefits:** ARNI therapy provides 20% cardiovascular death reduction and 21% heart failure hospitalization reduction compared to enalapril. **📊 Monitoring Protocol:** Enhanced surveillance for angioedema, hypotension, and renal function required during first 2-4 weeks post-transition.


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/arni-transition-protocols.html) · Markdown synchronized October 3, 2026.